Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy

Drug Delivery

Volumn 24, Issue 1, 2017, Pages 402-413

  Li, Shu Juan ^a   Wang, Xiao Juan ^a   Hu, Jing Bo ^a   Kang, Xu Qi ^a   Chen, Li ^b   Xu, Xiao Ling ^a   Ying, Xiao Ying ^a   Jiang, Sai Ping ^b   Du, Yong Zhong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Acute lung injury; ICAM 1; Lung targeting; Nanostructured lipid carriers; Simvastatin delivery

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 6; NANOCARRIER; SIMVASTATIN; TUMOR NECROSIS FACTOR; ANTIBODY; DRUG CARRIER; NANOMATERIAL;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXICITY; DISSOLUTION; DRUG DELIVERY SYSTEM; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IMMUNOFLUORESCENCE; IN VIVO STUDY; INFLAMMATORY CELL; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; VASCULAR ENDOTHELIAL CELL; ZETA POTENTIAL; A-549 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DOSE RESPONSE; METABOLISM; PROCEDURES; RANDOMIZATION;

A549 CELLS; ACUTE LUNG INJURY; ANIMALS; ANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; PARTICLE SIZE; RANDOM ALLOCATION; SIMVASTATIN;

EID: 85021857751     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717544.2016.1259369     Document Type: Article

References (34)

1. Ansar M, Serrano D, Papademetriou I, et al. (2013). Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting. ACS Nano 7:10597-611.
2. Bhowmick T, Berk E, Cui X, et al. (2012). Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J Control Release 157:485-92.
3. Bouis D, Hospers GA, Meijer C, et al. (2001). Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 4:91-102.
4. Calderon AJ, Bhowmick T, Leferovich J, et al. (2011). Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release 150: 37-44.
5. Chai GH, Hu FQ, Sun J, et al. (2014). Transport pathways of solid lipid nanoparticles across Madin-Darby canine kidney epithelial cell monolayer. Mol Pharm 11:3716-26.
6. Chen W, Pendyala S, Natarajan V, et al. (2008). Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am J Physiol Lung Cell Mol Physiol 295:L575-83.
7. Chen W, Sammani S, Mitra S, et al. (2012). Critical role for integrin-β4 in the attenuation of murine acute lung injury by simvastatin. Am J Physiol Lung Cell Mol Physiol 303:L279-85.
8. Cornier MA, Eckel RH. (2015). Non-traditional dosing of statins in statin-intolerant patients-is it worth a try? Curr Atheroscler Rep 17: 475.
9. Craig TR, Duffy MJ, Shyamsundar M, et al. (2011). A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med 183:620-6.
10. Du YZ, Weng Q, Yuan H, et al. (2010). Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery. ACS Nano 4:6894-902.
11. Gentile F, Curcio A, Indolfi C, et al. (2008). The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnol 6:9.
12. Gotts JE, Matthay MA. (2011). Mesenchymal stem cells and acute lung injury. Crit Care Clin 27:719-33.
13. Howard M, Zern BJ, Anselmo AC, et al. (2014). Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano 8:4100-32.
14. Hsu J, Northrup L, Bhowmick T, et al. (2012). Enhanced delivery of a-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine 8:731-9.
15. Huo M, Gao R, Jiang L, et al. (2013). Suppression of LPS-induced inflammatory responses by gossypol in RAW 264.7 cells and mouse models. Int Immunopharmacol 15:442-9.
16. Jacobson JR, Barnard JW, Grigoryev DN, et al. (2005). Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288:L1026-32.
17. Jacobson JR, Dudek SM, Birukov KG, et al. (2004). Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30:662-70.
18. Kilic B, Kruse M, Stahlmann R. (2006). The in vitro effects of quinupristin/dalfopristin, erythromycin and levofloxacin at low concentrations on the expression of different cell adhesion molecules on the surface of endothelial cells (Eahy926). Toxicology 218:30-8.
19. Lanbeck P, Odenholt I, Riesbeck K. (2004). Dicloxacillin and erythro-mycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother 53:174-9.
20. Lu YM, Huang JY, Wang H, et al. (2014). Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. Biomaterials 35:530-7.
21. Mathew B, Huang Y, Jacobson JR, et al. (2011). Simvastatin attenuates radiation-induced murine lung injury and dysregulated lung gene expression. Am J Respir Cell Mol Biol 44:415-22.
22. Matthay MA, Zemans RL. (2011). The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 6: 147-63.
23. McClintock D, Zhuo H, Wickersham N, et al. (2008). Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 12:R41.
24. Muller HC, Hellwig K, Rosseau S, et al. (2010). Simvastatin attenuates ventilator-induced lung injury in mice. Crit Care 14:R143.
25. Muro S, Garnacho C, Champion JA, et al. (2008). Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 16:1450-8.
26. Oh B, Lee M. (2014). Combined delivery of HMGB-1 box A peptide and S1PLyase siRNA in animal models of acute lung injury. J Control Release 175:25-35.
27. Radjabova V, Mastroeni P, Skjodt K, et al. (2015). TARM1 is a novel leukocyte receptor complex-encoded ITAM receptor that costimulates proinflammatory cytokine secretion by macrophages and neutrophils. J Immunol 195:3149-59.
28. Sadikot RT. (2014). The potential role of nano-and micro-technology in the management of critical illnesses. Adv Drug Deliv Rev 77: 27-31.
29. Shyamsundar M, McKeown ST, O’Kane CM, et al. (2009). Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107-14.
30. Steiner S, Speidl WS, Pleiner J, et al. (2005). Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111:1841-6.
31. Tang X, Wang G, Shi R, et al. (2015). Enhanced tolerance and antitumor efficacy by docetaxel-loaded albumin nanoparticles. Drug Deliv 23:2686-96.
32. Yuan H, Chen CY, Chai GH, et al. (2013). Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm 10:1865-73.
33. Yu Q, Hu X, Ma Y, et al. (2016). Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 23:1469-75.
34. Zhai Y, Zhai G. (2014). Advances in lipid-based colloid systems as drug carrier for topic delivery. J Control Release 193:90-9.